Submit manuscript...
Journal of
eISSN: 2373-4396

Cardiology & Current Research

Editorial Volume 8 Issue 6

Ventricular Arrhythmias and Sudden Cardiac Death in Patients with Chagas Disease

Osmar Antonio Centurión, Laura Beatriz García

Department of Health Sciences?s Investigation, Sanatorio Metropolitano, Fernando de la Mora, Paraguay

Correspondence: Osmar Antonio Centurión, Professor of Medicine, Asuncion National University, Department of Health Sciences’s Investigation, Sanatorio Metropolitano, Teniente Ettiene 215 c/ Ruta Mariscal Estigarribia, Fernando de la Mora, Paraguay

Received: April 27, 2017 | Published: May 5, 2017

Citation: Centurión OA (2017) Ventricular Arrhythmias and Sudden Cardiac Death in Patients with Chagas Disease. J Cardiol Curr Res 8(6): 00301. DOI: 10.15406/jccr.2017.08.00301

Download PDF

Editorial

Chagas disease is a parasitic zoonosis caused by Trypanosoma cruzi which is transmitted by insects belonging to different species of Triatoma. Nevertheless, several other routes of transmission have also been described, such as transmission via blood transfusion, infected organs transplant, and oral transmission [1-5]. Following the acute phase of the infection, untreated Chagas’ disease enters a chronic phase that is initially asymptomatic or unrecognized. It is estimated that nearly one third of the patients infected with T. cruzi will develop symptomatic heart disease during the course of their lives [6-10]. The pathogenesis of the Chagas heart disease (CHD) is not clearly understood yet. Current knowledge of the physiopathology of this disease, as well as, the scientific understanding of the medical based evidence points towards a complex etiology. There is evidence of direct involvement of parasites in producing myocardial damage [11-14]. The possibility of a mechanism associated to autoimmune phenomenon was also described [15-18]. Other described pathogenic mechanisms include microvascular alterations and autonomic denervation [19-21].

Carlos Chagas described the disease that bears his name in 1909. The next year he emphasized the importance of the abnormalities in the cardiac rhythm found in some patients with chronic disease. Hence, he then already suggested the existence of heart involvement in patients with chronic Chagas disease [22-25]. He noticed the presence of premature ventricular contractions (PVC) and stressed the presence of AV block in cases of extreme bradycardia during physical examination as cause of abnormalities in the cardiac rhythm. Carlos Chagas presented cases of patients with heart failure and frequent PVC who were found to have nests of parasites accompanied by interstitial mononuclear cell infiltration in the myocardium at autopsy [26-28]. Therefore, he suggested that PVC on physical examination could herald sudden cardiac death (SCD) in the cardiac form of the chronic disease [29-31].

Low LV ejection fraction and VO2 max remained independent predictors of all cause mortality in patients with chronic heart failure secondary to chronic CHD. In addition, ventricular tachycardia induced by exercise stress testing was found to be a predictor of sudden cardiac death in patients with chronic CHD [32-36]. Rochitte et al. [37] quantified myocardial fibrosis by magnetic resonance imaging in patients with chronic CHD. They observed that myocardial fibrosis was present in 85% of patients with this condition, and that LV ejection fraction was inversely correlated to myocardial fibrosis. The authors demonstrated that myocardial fibrosis was present in all patients with ventricular tachycardia, a fact that strongly suggest a role for the fibrosis in the pathogenesis of malignant arrhythmias in patients with chronic CHD [37].

Chagas heart disease is a fibrotic disease that is generally located in the posteroinferior and apical region of the left ventricle, the sinus node, and the conduction system below the bundle branch. CHD often develop as a form of dilated cardiomyopathy with a tendency towards the formation of apical aneurysms. It has a powerful arrhythmogenic potential leading to ventricular arrhythmias and sudden cardiac death. Also CHD is often associated with bradyarrhythmias due to atrioventricular block or sinus node disease. In the natural course of the disease, the cardiac abnormalities appear progressively around 20 to 30 years following infection [21, 22]. On the other hand, during the acute phase of the infection nearly 10% of the patients develop myocarditis that progresses rapidly towards a severe form of CHD [38,39]. Other patients with mild cardiac involvement who are in the chronic phase of the disease may develop sudden exacerbation and acute heart failure when exposed to conditions of immunosuppression [39].

There is no characteristic pattern of CHD in the conventional electrocardiogram. However, an isolated right bundle-branch block or its association with left anterior hemiblock in patients with positive serology can be considered indicators of chronic CHD [40-42]. Patients with symptomatic CHD should be considered to be at increased risk of SCD. It is important to remember that SCD can often be the first manifestation of CHD [43,44]. It was observed that during the chronic phase of the clinical evolution of the patients suffering from CHD, some of them died suddenly and unexpectedly. Unexpected SCD is one of the main mechanisms of mortality in patients suffering from Chagas disease. SCD occurs in a significant number of subjects in whom no previous symptoms or relevant symptoms were detected during clinical follow-up [43,44]. The presence of repolarization disorders have been described preceding sudden and global asynchrony. The dispersion of the QT interval is present in 20-30% of infected subjects not suffering from any other symptoms. Therefore, it is necessary to evaluate the dispersion of the QT interval and variability of the heart rate in Chagas disease since its association with ventricular arrhythmia and sudden unexpected death in patients infected with T. cruzi has been proven [7-9].

In this setting even nonspecific symptoms as weakness or dizziness have much more significance as they may be predictive of an episode of syncope. Patients with CHD often develop premature ventricular contractions and tachycardias, most commonly associated with myocardial damage that generates reentry phenomena. Most sustained ventricular tachyarrhythmias in patients with CHD do not arise from the apical aneurysm of the left ventricle but rather from the inferolateral region [45,46]. Since these malignant arrhythmias develop within a progressive abnormality with multiple arrhythmogenic foci, radiofrequency ablation is not so effective and should not be considered as first choice therapeutic technique. Despite the absence of specific studies in chronic CHD, the implantation of an implantable cardioverter defibrillator (ICD) is recommended to reduce the risk of sudden death in cases of clinical sustained ventricular tachycardia, or in monomorphic sustained ventricular tachycardia developing during the electrophysiological study. The administration of amiodarone is a possibility in patients with nonsustained ventricular tachycardia and normal noninducible electrophysiological study. Amiodarone is also administered empirically in an effort to reduce the frequency of appropriate or inappropriate ICD discharges and lower the likelihood of electrical storm. If the patient receives too many discharges despite this pharmacological treatment, radiofrequency ablation should be considered [47,48].

References

  1. Kun H, Moore A, Mascola L, Steurer F, Lawrence G et al. (2009) Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 48(11): 1534-1540.
  2. Murcia L, Carrilero B, Saura D, Iborra MA, Segovia M (2013) Diagnóstico y tratamiento de la enfermedad de Chagas. Enferm Infecc Microbiol Clin 31(Supl 1): 26-34.
  3. Pérez-Molina JA, Norman F, López-Vélez R (2012) Chagas disease in non-endemic countries: Epidemiology, clinical presentation and treatment. Curr Infect Dis Rep 14(3): 263-274.
  4. Rassi A, Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375:1388-1402.
  5. Rodríguez-Guardado A, Rodriguez M, Alonso P, Seco C, Flores-Chavez M, et al. (2009) Serological screening of Chagas disease in an immigrant population in Asturias, Spain proceeding from Chagas-endemic areas. Scand J Infect Dis 41(10): 774-776.
  6. Stoloff Groppo A, Higushi L, Bocchi E, Bellotti G, Auler JO, et al. (1987) Heart Transplantation in patients with Chagas Disease cardiomyopathy. J Heart Transplant 6(5): 307-312.
  7. Mitelman J, Giménez L, Romero Villanueva H, y col (2004) Electrocardiografía de alta resolución para la detección de alteraciones funcionales miocárdicas en Chagas indeterminado. Tem de Cardiol 5: 9-12.
  8. Mitelman J, Giménez L, Palacios K, y col (2006) Anticuerpos antirreceptores a neurotransmisores y su correlación con la alteración de la dispersión del QT y de la variabilidad de la frecuencia cardíaca. Reblampa 19(3): 408-415.
  9. Andres DS, Irurzum IM, Defeo MM, y col (2008) Detecting Subclinical Alterations in Early Stages of Chagas Disease Through Holter. Circulation 118(12): e258.
  10. Ferreira Simao (1999) Chagas Disease and inmunossupression. Mem Inst Oswaldo Cruz, Rio de Janeiro 94(Supl 1): 325-327.
  11. Baruch WA, Arribada JA, Bulla DH, Carlier Y, Rodrigues J, Chuit R, et al. (2005) Consulta Técnica Regional OPS/MSF sobre Organização e estrutura da atenção médica do doente e infectado por Trypanosoma cruzi/doença de Chagas. Rev Soc Bras Med Trop 38: 538-541.
  12. Dias JCP (1995) Natural history of Chagas’ disease. Arq Bras Cardiol 65(4):359-366.
  13. Bellotti G, Bocchi EA, De Moraes AV, Higuchi ML, Barbero-Marcial M, et al. (1996) In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am Heart J 131(2): 301-307.
  14. Higuchi ML, de Brito T, Reis MM, Barbosa A, Bellotti G, et al. (1993) Correlation between Trypanosoma cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc Pathol 2(2): 101-106.
  15. Takle GB, Hudson L (1989) Autoimmunity and Chagas’ disease. Curr Top Microbiol Immunol 145: 79-92.
  16. López L, Arai K, Jiménez E, Jiménez M, Pascuzo C, et al. (2006) C-Reactive Protein and Interleukin-6 serum levels increase as Chagas disease progreses towards cardiac failure. Rev Esp Cardiol 59(1): 50-56.
  17. Rossi MA (1990) Microvascular changes as a cause of chronic cardiomyopathy in Chagas’ disease. Am Heart J 120(1): 233-236.
  18. Tafuri WL (1999) Immunopathology of Chagas disease: a historical overview. Mem Inst Oswaldo Cruz Suppl: 247-248.
  19. Marin-Neto JA (1998) Cardiac dysautonomia and pathogénesis of Chagas’ heart disease. Int J Cardiol 66(2): 29-131.
  20. Dávila-Spinetti DF, Colmenarez-Mendoza HL, Lobo-Vielma L (2005) Mecanismos causantes de la progresión del daño miocárdico en la enfermedad de Chagas crónica. Rev Esp Cardiol 58(9): 1007-1009.
  21. Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, et al. (2005) Indicadores clínicos de progresión de la miocaditis chagásica crónica. Rev Esp Cadiol 58(9): 1037-1044.
  22. Chagas C (1916) Pathogenic processes of American trypanosomiasis. Mem Inst Oswaldo Cruz 8: 3-38.
  23. Bestetti RB, Martins CA, Cardinalli-Neto A (2009) Justice where justice is due: A posthumous Nobel Prize to Carlos Chagas (1879-1934), the discoverer of American Trypanosomiasis (Chagas’ disease). Int J Cardiol 134(1): 9-16.
  24. Chagas C (1910) Aspecto clínico geral da nova entidade mórbida produzida pelo Schizotrypanum cruzi (Nota Prévia). Brazil-Médico 24(27): 263-265.
  25. Chagas C (1910) Nova entidade mórbida do homem. Brazil-Médico 45: 443-447.
  26. Vianna G (1911) Contribuição para o estudo da anatomia patológica de Carlos Chagas. Mem Inst Oswaldo Cruz 3: 276-294.
  27. Chagas C (1911) Nova entidade mórbida do homem. Resumo geral de estudos etiológico e clínico. Mem Inst Oswaldo Cruz 3: 3-59.
  28. Chagas C (1912) O mal de Chagas. Arch Soc Med Cir S Paulo 3: 34-66.
  29. Chagas C (1916) Processos patogênicos da trypanosomiase americana. Mem Inst Oswaldo Cruz 8: 5-35.
  30. Bestetti RB, Cardinalli-Neto A, Restini CB, Couto LB (2016) Could Carlos Chagas’ assumption on the relationship between goiter and chronic Chagas heart disease be correct? A historical reappraisal. Int J Cardiol 202: 410-412.
  31. Chagas C, Villela E (1922) Cardiac form of American Trypanosomiasis. Mem Inst Oswaldo Cruz 14: 5-91.
  32. Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, et al. (1994) Survival and predictors of survival in patients with congestive heart failure due to Chagas’ cardiomyopathy. Circulation 90(6): 3098-3102.
  33. de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE (1995) Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J 74(3): 293-295.
  34. Bestetti RB, Dalbo CM, Arruda CA, Correia Filho D, Freitas OC (1996) Predictors of sudden cardiac death for patients with Chagas’ disease: a hospital-derived cohort study. Cardiology 87(6): 481-487.
  35. Cabot R (2014) The four common types of heart-disease. JAMA 63(17):1461-1463.
  36. Sánchez G, Coronado X, Zulantay I, Apt W, Gajardo M,et al. (2005) Monitoring the efficacy of specific treatment in chronic Chagas disease by polymerase chain reaction and flow cytometry analysis. Parasite 12(4): 353-357.
  37. Rochitte CE, Oliveira PF, Andrade JM, Ianni BM, Parga JR, et al. (2005) Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol 46(8): 1553-1558.
  38. Prata A (1959) Prognóstico e complicações da doença de Chagas. Rev Goiana Med 5: 87-96.
  39. Simoes MV, Nonino A, Simoes BP, Almeida-Filho OC, Maciel BC, et al. (1994) Reagudization of Chagas myocarditis inducing exclusive right ventricular failure. Arq Bras Cardiol 62(6): 435-437.
  40. Laranja FS, Dias E, Nobrega G, Miranda A (1956) Chagas’ disease: a clinical, epidemiologic, and pathologic study. Circulation 14(6): 1035-1060.
  41. Maguire JH, Hoff R (1987) Cardiac morbidity and mortality due to Chagas disease: prospective eletrocardiographic study of a Brazilian community. Circulation 75: 1140-1145.
  42. Dias JCP, Kloetzel K (1968) The prognostic value of the electrocardiographic features of chronic Chagas’disease. Rev Inst Med Trop São Paulo 10(3):158-162.
  43. Prata A, Lopes ER, Chapadeiro E (1986) Características da morte súbita tida como não esperada na doença de Chagas. Rev Soc Bras Med Trop 19(1): 9-12.
  44. Rassi A Jr, Rassi SG, Rassi A (2001) Sudden death in Chagas’ disease. Arq Bras Cardiol 76(1): 75-96.
  45. Oliveira JS, Mello de Oliveira JA, Frederigue U Jr, Lima Filho EC (1981) Apical aneurysm of Chagas’ heart disease. Br Heart J 46: 432-437.
  46. Sarabanda A, Sosa E, Scanavacca M, Magalhäes L, Kuniyoshi R, et al. (1994) Correlação entre a morfologia da taquicardia ventricular sustentada e a ventriculografia esquerda na cardiopatia chagásica crônica. Rev Bras Marcapasso e Arritmias 7: 143.
  47. Sosa E, Scalabrini A, Rati M, Bellotti G, Pileggi F (1987) Successful catheter ablation of the «origin» of recurrent ventricular tachycardia in chronic chagasic heart disease. J Electrophysiol 1: 5861.
  48. Sosa E, Scanavacca M, D’Avila A, Bellotti G, Pilleggi F (1999) Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic chagasic heart disease. Pacing Clin Electrophysiol 22(1): 128-130.
Creative Commons Attribution License

©2017 Centurión, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.